Among patients with triple negative breast cancers (TNBC) and HER2+ cancers, a significantly larger proportion underwent NACT compared to the HR+/HER2-patients, and significantly more patients with AJCC stage 3 disease received NACT compared to patients with stage 2 disease (33.5% vs. 18.9%; p = 0.007). The gene discussed is HR; the disease is triple-negative breast carcinoma.